Literature DB >> 18401832

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.

V Fonseca1, M Baron, Q Shao, S Dejager.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18401832     DOI： 10.1055/s-2008-1058090

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN： 0018-5043            Impact factor:   2.936


× No keyword cloud information.
  33 in total

1.  Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.

Authors:  Yan-Ling He; Jessica Valencia; Yiming Zhang; Sherwyn L Schwartz; Monica Ligueros-Saylan; James Foley; William P Dole
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 3.  Vildagliptin: a review of its use in type 2 diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 4.  Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Authors:  Rimke C Vos; Mariëlle Jp van Avendonk; Hanneke Jansen; Alexander N Goudswaard; Maureen van den Donk; Kees Gorter; Anneloes Kerssen; Guy Ehm Rutten
Journal:  Cochrane Database Syst Rev       Date:  2016-09-18

5.  Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.

Authors:  Deborah Layton; Abigail L Coughtrie; Naseer Qayum; Saad A W Shakir
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

6.  The incretin hormones: from scientific discovery to practical therapeutics.

Authors:  S Mudaliar; R R Henry
Journal:  Diabetologia       Date:  2012-05-04       Impact factor: 10.122

Review 7.  Vildagliptin: a review of its use in type 2 diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 8.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

Review 9.  Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

Authors:  James E Foley; Jens Jordan
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 10.  Vildagliptin: a new oral treatment for type 2 diabetes mellitus.

Authors:  Chantal Mathieu; Evy Degrande
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.